Author: Fiona Craig

  • PPHE Hotel Group completes $33.5 million sale of Manhattan development site

    PPHE Hotel Group completes $33.5 million sale of Manhattan development site

    PPHE Hotel Group (LSE:PPH) has completed the disposal of a development site in Manhattan, New York, for $33.5 million, delivering on a previously announced agreement to sell the property to a US real estate developer.

    The transaction provides the international hospitality group with additional capital to reduce debt and reinvest elsewhere in its portfolio as part of its wider capital allocation strategy.

    Sale proceeds used to reduce debt

    PPHE used $6.75 million of the proceeds from the Manhattan disposal to repay debt associated with the development site.

    The remaining proceeds will be allocated in accordance with the group’s capital allocation priorities, providing additional flexibility to invest in its existing portfolio and pursue other strategic opportunities.

    The disposal reflects PPHE’s approach to actively managing its property holdings and balance sheet, including realising value from assets where management believes capital can be deployed more effectively elsewhere.

    Financial improvement offset by leverage

    PPHE’s financial outlook remains mixed. The group delivered strong revenue growth and moved into positive free cash flow during 2025, providing evidence of improving underlying cash generation.

    However, leverage remains elevated, while profitability deteriorated notably in 2025 compared with the previous year. These factors continue to represent key financial risks for the group.

    Technical indicators also remain under pressure, with PPHE’s share price trading below important moving averages and its MACD in negative territory.

    Valuation provides another potential headwind given the company’s relatively high price-to-earnings multiple, although its dividend yield offers some support to shareholders.

    More about PPHE Hotel Group

    PPHE Hotel Group is an international hospitality real estate company with a portfolio valued at approximately £2.2 billion, primarily comprising prime freehold and long leasehold properties across Europe.

    The group owns, co-owns, develops, leases, operates and franchises upscale and lifestyle hotels, resorts and campsites. It holds exclusive rights to the Park Plaza brand across Europe, the Middle East and Africa and also operates properties under the art’otel and Arena brands.

  • Real Estate Investors targets debt-free position as Midlands portfolio sales accelerate

    Real Estate Investors targets debt-free position as Midlands portfolio sales accelerate

    Real Estate Investors Plc (LSE:RLE) is targeting the elimination of its remaining debt and the return of capital to shareholders as it accelerates the disposal of its Midlands commercial property portfolio.

    The company has navigated subdued conditions across the UK commercial property market by pushing more of its planned asset sales into the latter part of 2026. While transaction volumes remain depressed and office valuations have faced pressure, stronger retail occupier demand and falling vacancy levels have helped stabilise and, in some cases, improve portfolio values.

    Asset disposals advance as debt reduction continues

    Since April 2026, REI has placed £15.7 million of property under offer, of which £10.7 million has already been exchanged or completed. These transactions were agreed at an average of 92% of the assets’ December 2025 book value.

    Further, larger disposals are planned for the fourth quarter of 2026. Management expects completion of the existing sales pipeline to generate sufficient proceeds to repay all outstanding borrowings.

    Achieving a debt-free position would allow the company to begin returning capital to shareholders as its portfolio wind-down progresses. REI also believes the remaining portfolio could attract interest from regional buyers seeking a larger-scale transaction.

    New lettings set to lift occupancy and rental income

    Operational performance across the portfolio continues to improve, with contracted lettings representing almost £400,000 of additional annual rent.

    Once these agreements complete, occupancy is expected to increase to 82.2% from 78.0%, while annual rental income is forecast to rise to £8.1 million from £7.7 million.

    Rent collection remains above 99%, while the portfolio has a weighted average unexpired lease term of almost six years. Recent leasing activity involving occupiers including Matalan, Argos, Popeyes and McDonald’s is also supporting property values ahead of planned disposals.

    Borrowings expected to fall to £24 million

    REI has already reduced debt substantially, with borrowings declining to £29.2 million from £34.2 million at the end of 2025.

    Debt is expected to fall further to approximately £24 million by mid-October 2026 following completion of property sales that have already exchanged.

    The company has repaid its Barclays facilities in full, leaving NatWest and Lloyds as its remaining lenders. Current borrowings carry an average cost of 5.75%, with REI maintaining conservative leverage and remaining compliant with its banking covenants.

    Quarterly dividend policy remains in place

    Although portfolio disposals inevitably reduce rental income, REI continues to prioritise shareholder distributions during the wind-down.

    The company paid a fully covered first-quarter 2026 dividend of 0.375p per share, taking cumulative distributions since the introduction of its dividend policy to £57.4 million.

    Management remains committed to maintaining covered quarterly dividends without interruption, although future payments will depend partly on the pace of disposals.

    REI also remains open to a broader corporate transaction if an appropriate proposal could accelerate the portfolio realisation process while delivering additional value to shareholders.

    Financial outlook improves as leverage falls

    The company’s financial performance remains under pressure following several years of declining revenue and recent losses. However, continued positive free cash flow and the rapid reduction in borrowings provide support as the disposal strategy progresses.

    Technical indicators remain weak, including a negative MACD and very low RSI. From a valuation perspective, the investment case is mixed, with a relatively attractive dividend yield offset by a negative price-to-earnings ratio resulting from recent losses.

    More about Real Estate Investors Plc

    Real Estate Investors Plc is a Midlands-focused real estate investment trust specialising in a diversified portfolio of commercial properties spanning retail, offices and other sectors.

    The internally managed REIT is structured to avoid excessive dependence on any individual property or tenant and benefits from tax-efficient treatment of qualifying rental income and capital gains.

    REI is currently implementing a multi-year orderly disposal of its property portfolio, with proceeds primarily directed towards debt repayment while the company seeks to maintain fully covered quarterly dividends and ultimately return surplus capital to shareholders.

  • Trellus Health moves towards administration after running short of funds

    Trellus Health moves towards administration after running short of funds

    Trellus Health plc (LSE:TRLS) is moving towards administration after its board concluded that the AIM-listed digital healthcare company no longer has sufficient funding to continue operating as a going concern.

    The company has filed a notice of intention to appoint administrators from Quantuma Advisory, a step intended to protect the interests of creditors while options for the business and its assets are assessed.

    Trellus Health pursues asset sales

    As part of the restructuring process, Trellus Health is seeking buyers for certain assets, including its US operating subsidiary, Trellus Health Inc.

    However, the board expects that any transaction arising from the sale process will generate no return for existing shareholders. Creditors will therefore take priority as the company attempts to realise value from its remaining operations and intellectual property.

    Trellus Health’s shares remain suspended from trading on AIM, with the company saying further announcements will be made as developments occur.

    Administration threatens independent future

    The decision represents a significant setback for Trellus Health’s strategy of building a standalone digital chronic care management business.

    With available funding exhausted, the company’s technology, operating businesses and other assets are now more likely to be sold or separated through the restructuring process rather than developed under Trellus Health as an independent listed company.

    Existing shareholders face the prospect of losing their entire investment, highlighting the financing and scaling challenges encountered by specialist digital healthcare companies seeking to commercialise technology-intensive care platforms.

    Financial losses outweigh technical momentum

    Trellus Health’s financial position has been characterised by substantial ongoing losses, negative free cash flow and declining shareholders’ equity, despite the company carrying no debt.

    Technical indicators had provided a more positive signal, with the shares showing momentum above major moving averages before the suspension. However, the company’s loss-making financial position, lack of a dividend and impending administration substantially outweigh those technical factors.

    More about Trellus Health plc

    Trellus Health plc is a healthcare technology company focused on helping patients manage complex chronic conditions through digital tools and personalised resilience-based programmes.

    Its Trellus Elevate platform combines data analytics, specialist coaching and individualised support, initially targeting gastrointestinal conditions such as inflammatory bowel disease. The platform is designed to improve patient self-management while reducing hospital admissions and emergency care utilisation.

    The company also developed Trellus TrialSet, which provides pharmaceutical partners with support across clinical development and post-commercialisation patient engagement.

    Founded by specialists from Mount Sinai with expertise in inflammatory bowel disease, Trellus Health joined AIM in May 2021 under the ticker TRLS. Its broader strategy has been to apply its resilience methodology and technology-enabled care model across multiple chronic conditions while demonstrating clinical benefits and potential cost savings for healthcare systems.

  • Truetide seeks shareholder approval for AI-focused investment strategy

    Truetide seeks shareholder approval for AI-focused investment strategy

    Truetide plc (LSE:TRUE) is seeking shareholder approval for a substantial expansion of its investing policy that would introduce a dedicated artificial intelligence strategy alongside its existing focus on technology and knowledge-intensive businesses.

    The proposed changes follow a review of developments across the AI market. Truetide’s board sees an increasingly clear distinction between established, cash-generative companies using AI to strengthen their businesses and heavily funded growth companies whose elevated valuations may prove more difficult to sustain.

    New strategy combines long positions with defined-risk shorts

    Under the revised policy, Truetide intends to construct a diversified global portfolio combining long investments in companies that enable or benefit from AI with defined-risk short exposure.

    Any short exposure would be established exclusively through purchased options, limiting potential losses to the premium paid rather than exposing the company to the unlimited downside associated with conventional short selling.

    The strategy would be funded using available cash and proceeds from the orderly disposal of investments considered non-core to the revised portfolio.

    Truetide believes the approach could improve risk-adjusted returns while giving the company greater flexibility to benefit from both rising and falling valuations within the rapidly developing AI sector.

    Investment limits and hedging rules to be formalised

    The proposed policy also introduces clearer risk controls covering individual portfolio positions and the amount that can be committed to option premiums.

    It would formally establish the company’s ability to use hedging techniques and protective collars, providing additional tools for managing downside risk while retaining exposure to potential gains.

    Alongside the new global AI strategy, Truetide would retain its existing approach to investing in UK-focused technology and knowledge-intensive businesses at both earlier and later stages of development.

    General meeting scheduled for September

    Shareholders will vote on the revised investing policy at a general meeting scheduled for 7 September 2026.

    The meeting will consider a single resolution approving the changes, which require shareholder consent under AIM rules governing material amendments to an investing company’s policy.

    If approved, the new strategy will become effective immediately. It would broaden Truetide’s potential investment universe across international markets while maintaining governance restrictions covering gearing, cross-holdings and the financial instruments available to the company.

    Financial performance remains a challenge

    Truetide’s investment outlook continues to be constrained by weak financial performance, including declining revenue, persistent operating losses and continued cash consumption. These pressures are partly mitigated by relatively low levels of debt.

    Technical indicators present a mixed picture, with a positive MACD countered by softer short-term momentum and neutral-to-weak RSI readings. The company’s loss-making position also results in a negative price-to-earnings ratio, while the absence of a dividend yield provides little additional support from an income perspective.

    More about Truetide plc

    Truetide plc is an AIM-quoted investing company targeting opportunities across technology and knowledge-intensive industries, including healthcare and professional services.

    Its strategy covers listed and privately held companies at different stages of development, using equity and related financial instruments. The company can operate as a passive shareholder in undervalued listed businesses while taking a more active role in earlier-stage private investments, including representation on investee company boards.

    Truetide may also invest in restructuring, rescue or distressed situations where the board identifies opportunities to create value. Investments are generally made with a potential growth and exit horizon of between two and five years.

    The company can invest through intermediate entities and partnerships and may use its own shares as consideration for transactions, subject to cross-holding restrictions. Its investment framework is also structured to maintain appropriate separation from controlled investee businesses and preserve Truetide’s status as an investing rather than trading company.

  • Kazatomprom posts higher first-half revenue as uranium demand remains strong

    Kazatomprom posts higher first-half revenue as uranium demand remains strong

    Kazatomprom (LSE:KAP) delivered resilient results for the first half of 2026, with consolidated revenue increasing 9% year on year to almost KZT 718 billion as favourable uranium pricing and stable long-term market fundamentals supported the business.

    Although industry-wide cost inflation contributed to lower net profit and earnings per share, management pointed to continued strong demand for secure nuclear fuel supplies. The company said its uranium production remains effectively fully committed to customers, reflecting sustained demand across the global nuclear energy market.

    Regulatory changes reinforce national operator role

    During the period, Kazatomprom outlined a series of legislative changes in Kazakhstan covering subsoil use, uranium licensing and radioactive waste management.

    The new framework further strengthens the company’s central position as Kazakhstan’s national uranium operator, including its responsibilities across production and remediation activities. Changes to uranium licensing requirements and exploration arrangements are also expected to shape future development of the country’s uranium resources.

    Kazatomprom completed payment of its 2025 dividend and convened an extraordinary general meeting through absentee voting to consider major uranium supply agreements and changes to the board.

    Zhalpak processing facility enters operation

    The company also commissioned its Zhalpak processing facility, which initially has annual capacity of 500 tonnes.

    Kazatomprom plans to increase capacity at the facility to 900 tonnes per year during 2027, supporting the development of its production and processing infrastructure as it responds to long-term demand from nuclear utilities.

    Sulphuric acid project faces up to 12-month delay

    Progress at the TQZ sulphuric acid plant has been disrupted after construction activities were halted to allow for the recovery and examination of potential paleontological specimens discovered at the site.

    Kazatomprom now expects commissioning of the plant to be delayed by between six and 12 months. However, the company currently anticipates no material effect on its uranium mining operations as a result of the postponement.

    Management said 2027 production guidance will be adjusted if necessary as the situation develops.

    Investor mine tour planned for October

    Kazatomprom plans to host a mine tour for analysts and shareholders in October 2026 as part of its efforts to strengthen engagement with the investment community and provide greater visibility into its operations.

    The group’s longer-term outlook continues to benefit from high margins, strong returns on equity and relatively low leverage. These strengths are balanced by slower revenue and profit momentum and a significant reduction in trailing free cash flow.

    Technical indicators also remain a source of pressure, with the shares trading below important medium-term moving averages and the MACD remaining negative. Valuation and dividend yield, however, provide some support to the investment case.

    More about Kazatomprom

    National Atomic Company Kazatomprom JSC is Kazakhstan’s national uranium operator and one of the world’s leading producers of natural uranium concentrates, supplying nuclear utilities through international and long-term contracts.

    The company operates across uranium mining, processing and related services, with production centred primarily on in-situ recovery operations. Its activities support growing global demand for nuclear energy as a source of baseload, low-emission electricity.

    Kazatomprom operates within Kazakhstan’s evolving nuclear and subsoil regulatory framework, which includes tighter equity requirements for uranium production licences and a shift towards a contracting model for uranium exploration. The company also manages strategic mine developments, processing facilities and supply-chain infrastructure, giving it a central role in both Kazakhstan’s civil nuclear industry and the wider global uranium market.

  • ZCCM Investments Holdings swings to ZMW 4.9 billion loss in 2025

    ZCCM Investments Holdings swings to ZMW 4.9 billion loss in 2025

    ZCCM Investments Holdings (LSE:ZCC) recorded a significant deterioration in its consolidated financial performance for the year ended 31 December 2025, moving to a ZMW 4.9 billion loss from a ZMW 39.8 billion profit in the previous year.

    The reversal reflected a substantial decline in revenue from contracts with customers as well as the absence of the sizeable gains from subsidiary loan modifications that had boosted the group’s 2024 results.

    Earnings reverse as exceptional gains disappear

    The weaker performance resulted in ZCCM-IH moving from an operating profit in 2024 to an operating loss in 2025.

    Basic earnings per share also deteriorated sharply, falling from earnings of ZMW 247.80 per share in the previous year to a loss of ZMW 30.60 per share.

    The comparison highlights the impact of exceptional items recorded in 2024 and the more challenging underlying performance of the group’s mining, energy and related investments during 2025.

    Parent company reduces annual loss

    At the standalone company level, ZCCM-IH remained in the red but achieved a meaningful reduction in its annual loss.

    The company reported a loss of ZMW 1.9 billion for 2025, compared with ZMW 4.4 billion a year earlier. Higher investment income helped improve the result, although this was partly offset by negative net finance results.

    Group equity declines to ZMW 43 billion

    ZCCM-IH’s consolidated equity fell to ZMW 43.0 billion at the end of 2025 from ZMW 52.3 billion a year earlier.

    The reduction reflected the group’s annual loss, lower asset valuations and dividend distributions during the period. The weaker equity position points to increased balance-sheet constraints and highlights the volatility facing shareholders through the group’s exposure to mining and energy assets.

    More about ZCCM Investments Holdings

    ZCCM Investments Holdings Plc is a Zambian investment holding company with substantial interests across the mining, energy and associated services sectors.

    The group operates through eight wholly owned subsidiaries while also holding interests in several copper mining operations, energy producers and industrial businesses. Its portfolio gives ZCCM-IH exposure to Zambia’s extractive industries and power sector, spanning mining, processing and supporting infrastructure.

  • Gore Street board urges investors to reject Saba-backed wind-up proposals

    Gore Street board urges investors to reject Saba-backed wind-up proposals

    Gore Street Energy Storage Fund (LSE:GSF) has stepped up its opposition to proposals backed by major shareholder Saba Capital Management, calling on investors to reject resolutions that could ultimately lead to the investment company being wound up, liquidated or reorganised.

    In a supplementary notice issued ahead of its September Annual General Meeting, the board recommended that shareholders support resolutions one to 15 while voting against two additional resolutions submitted by Saba, which owns approximately 18% of Gore Street’s ordinary shares.

    Board warns of forced sales at unfavourable valuations

    Saba is seeking to discontinue Gore Street as an investment vehicle and require the board to bring forward proposals that could result in a wind-up, liquidation or restructuring of the company.

    Gore Street’s directors argue that pursuing this course at the current point in the market cycle risks destroying shareholder value by effectively forcing the fund to sell assets when market conditions remain challenging.

    Instead, the board pointed to the revised strategy unveiled in March, which includes selective portfolio disposals and quarterly distributions to shareholders. Planned battery augmentation projects are also expected to increase revenue generation and enhance asset values.

    The company has established performance indicators as part of the strategy, with shareholders due to receive an opportunity to vote on Gore Street’s continuation if the specified targets are not achieved.

    Gore Street says discontinuation could disrupt asset sales

    The board also warned that approving Saba’s proposals could interfere with transactions already under way, including asset disposals announced this week.

    Directors believe completing these transactions alongside planned portfolio improvements offers shareholders a better opportunity to realise the underlying value of Gore Street’s assets than an immediate discontinuation and forced-sale process.

    With the board arguing that Saba’s proposals could benefit from low shareholder participation, Gore Street is encouraging investors to resubmit their proxy instructions so that votes on all resolutions, including the two contested motions, reflect broader shareholder participation.

    Financial weakness weighs on outlook

    Gore Street’s investment outlook continues to face pressure from volatile financial performance, including a substantial recent loss and a reduction in shareholders’ equity. Technical indicators are also weak, with the shares trading below key moving averages.

    These pressures are partly balanced by the fund’s absence of debt, positive free cash flow in its latest financial year and a comparatively high dividend yield, which may increase its appeal to income-focused investors.

    More about Gore Street Energy Storage Fund

    Gore Street Energy Storage Fund is a London-listed investment company specialising in utility-scale energy storage infrastructure.

    Launched in 2018, the company was the first listed energy storage fund on the London market and has developed an internationally diversified portfolio spanning five electricity grid networks.

  • Optima Health schedules September AGM following PAM Healthcare expansion

    Optima Health schedules September AGM following PAM Healthcare expansion

    Optima Health plc (LSE:OPT) has confirmed the date of its 2026 Annual General Meeting alongside the publication of its latest annual report and accounts, as the occupational health specialist continues to integrate the significantly enlarged business created by its acquisition of PAM Healthcare.

    The UK provider of technology-enabled occupational health and wellbeing services completed the PAM Healthcare acquisition in March 2026. The transaction expanded Optima Health’s directly employed clinical workforce to more than 1,250 and strengthened its position across both the UK and Republic of Ireland.

    AGM to take place in Warrington

    Optima Health has distributed its Notice of Annual General Meeting and 2026 annual report and accounts to shareholders, with the AGM scheduled for 22 September 2026 at the group’s offices in Warrington.

    The documents will also be made available through the company’s investor website, providing shareholders with access to the latest financial and governance information ahead of the meeting.

    Financial improvement balanced by leverage risks

    The group’s outlook is supported by signs of improving financial performance, including stronger cash generation and a return to profitability. Positive technical trends also provide support to the investment case.

    However, these factors are balanced by valuation and financial risks. Optima Health trades on a relatively high price-to-earnings multiple, while leverage has increased sharply following the expansion of the business. Margins also remain comparatively thin, leaving the group’s financial position an important area for investors to monitor.

    More about Optima Health plc

    Optima Health plc is a UK provider of occupational health and wellbeing services, delivering clinically led and technology-supported solutions to organisations across the public and private sectors.

    Following the acquisition of PAM Healthcare in March 2026, the enlarged group employs more than 1,250 clinicians and works with over 1,000 associates. It delivers more than one million interventions annually through a nationwide clinic network and also maintains a leading position in Ireland through Optima Health Ireland and Corporate Health Ireland.

  • Aberforth Geared Value & Income Trust share price lags NAV growth in 2026

    Aberforth Geared Value & Income Trust share price lags NAV growth in 2026

    Aberforth Geared Value & Income Trust PLC (LSE:AGVI) has recorded strong net asset value growth during 2026, although its share price has failed to keep pace, creating a growing gap between the trust’s market valuation and the performance of its underlying portfolio.

    The investment trust has now been examined in a new detailed research report from the investment companies team at Kepler Trust Intelligence. The analysis is designed to give UK investors an independent reference point for assessing the trust, including its recent performance and current valuation.

    Kepler publishes new research on Aberforth trust

    Kepler’s report is available free of charge to UK investors through its Trust Intelligence platform and is presented as factual research rather than investment, financial or tax advice.

    The accompanying disclosures emphasise that historical performance should not be viewed as an indicator of future returns. Kepler Partners also notes that it may have commercial relationships with, or positions in, securities covered by its research.

    Investors are therefore encouraged to consider independent professional financial advice when evaluating Aberforth Geared Value & Income Trust, particularly when assessing the significance of the current difference between its share price and underlying net asset value performance.

    More about Aberforth Geared Value & Income Trust PLC

    Aberforth Geared Value & Income Trust PLC is a UK-listed investment trust providing geared exposure to value-focused equities. Its strategy is designed to generate a combination of long-term capital appreciation and income for shareholders.

    The trust’s shares are traded on the London market, giving investors access to a portfolio managed according to a value-investing approach. Its performance and valuation are also regularly followed by specialist research providers covering the UK investment trust sector.

  • Hunting lowers 2026 EBITDA outlook as Kuwait tender faces delay

    Hunting lowers 2026 EBITDA outlook as Kuwait tender faces delay

    Hunting (LSE:HTG) has reduced its EBITDA forecast for 2026 after Kuwait Oil Company (KOC) indicated that a delayed tender will be re-run, adding further pressure following a weaker first-half performance in OCTG and Advanced Manufacturing.

    First-half revenue and earnings decline

    Revenue for the first six months of the year fell 6% to $497.0 million from $528.6 million in the same period of 2025. EBITDA decreased 12% to $62.1 million from $70.2 million, while the EBITDA margin contracted to 12% from 13%.

    Adjusted profit before tax dropped to $34.5 million from $43.7 million, with adjusted diluted earnings per share declining to 15.2 cents from 19.6 cents.

    Hunting said the year-on-year reduction largely reflected KOC orders that were completed during the first half of 2025 but were not repeated this year, alongside softer activity within Advanced Manufacturing.

    Performance was stronger elsewhere in the portfolio, with Perforating Systems and Subsea Technologies delivering notable revenue growth supported by organic momentum. This helped partially offset weaker trading across OCTG, Advanced Manufacturing and other manufacturing operations.

    Cash flow weakens as net debt rises

    Free cash flow moved to an outflow of $27.8 million, compared with an inflow of $66.2 million a year earlier. Hunting ended the period with net debt of $51.4 million, against net cash of $44.7 million at the comparable point last year.

    Return on capital employed also declined, falling to 9.1% from 10.5%.

    Despite the softer financial performance, Hunting raised its interim dividend by 13% to 7.0 cents per share from 6.2 cents. The company said it continues to expect dividend distributions to increase by 13% annually through the end of the decade.

    Portfolio transformation supports stronger divisions

    CEO Jim Johnson, who has announced plans to retire, said the first-half performance demonstrated the benefits of Hunting’s portfolio transformation, pointing to strong margins in Subsea and record international sales from Perforating Systems.

    Johnson also noted that instability in the Middle East had disrupted some tendering activity, although Hunting expects business in the region to recover quickly once greater stability returns.

    Kuwait tender delay hits 2026 guidance

    Hunting said KOC has indicated that it intends to re-run the OCTG tender process originally launched in April. The resulting delay is expected to reduce the group’s 2026 EBITDA by approximately $10 million.

    As a result, Hunting has lowered its full-year 2026 EBITDA guidance to between $138 million and $141 million, slightly below its previous forecast. The company nevertheless expects to finish the year with a cash balance of approximately $50 million to $60 million.

    Looking further ahead, Hunting continues to anticipate year-on-year growth in 2027. However, the KOC tender delay could have a maximum negative impact of around $10 million on the current 2027 EBITDA consensus forecast of $165 million.